# 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)

> **NCT01124812** · PHASE1 · TERMINATED · sponsor: **Philogen S.p.A.** · enrollment: 3 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **OTHER:** 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy

## Key facts

- **NCT ID:** NCT01124812
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2011-08
- **Final completion:** 2012-10
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2012-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124812, "131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01124812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*